106861-44-3
Chemical Structure
Mivacurium dichloride
- CAS No.: 106861-44-3
- Formula:C58H80Cl2N2O14
- Molecular Weight:1100.17
IUPAC Name: (1R,1'R)-2,2'-((((E)-oct-4-enedioyl)bis(oxy))bis(propane-3,1-diyl))bis(6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-2-ium) chloride
InChIKey: WMSYWJSZGVOIJW-ONUALHDOSA-L
SMILES: O=C(OCCC[N+]1(C)[C@H](CC2=CC(OC)=C(OC)C(OC)=C2)C3=C(C=C(OC)C(OC)=C3)CC1)CC/C=C/CCC(OCCC[N+]4(C)[C@H](CC5=CC(OC)=C(OC)C(OC)=C5)C6=C(C=C(OC)C(OC)=C6)CC4)=O.[Cl-].[Cl-]
Biological Activity: Mivacurium dichloride is a benzylisoquinoline derivative and is a short-acting non-depolarizing neuromuscular blocking agent and skeletal muscle relaxant. Mivacurium dichloride couples with the nAChR to reduce or inhibit the depolarizing effect of acetylcholine on the terminal disc of the muscle cell[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mivacurium dichloride | 99.00% | Mivacurium dichloride is a benzylisoquinoline derivative and is a short-acting non-depolarizing neuromuscular blocking agent and skeletal muscle relaxant. Mivacurium dichloride couples with the nAChR to reduce or inhibit the depolarizing effect of acetylcholine on the terminal disc of the muscle cell. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mivacurium dichloride (Standard) | ≥98% | Mivacurium (dichloride) (Standard) is the analytical standard of Mivacurium (dichloride). This product is intended for research and analytical applications. Mivacurium dichloride is a benzylisoquinoline derivative and is a short-acting non-depolarizing neuromuscular blocking agent and skeletal muscle relaxant. Mivacurium dichloride couples with the nAChR to reduce or inhibit the depolarizing effect of acetylcholine on the terminal disc of the muscle cell. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Delu Che, et al. Mivacurium Induce Mast Cell Activation and Pseudo-Allergic Reactions via MAS-related G Protein Coupled receptor-X2. Cell Immunol. 2018 Oct;332:121-128. [Content Brief]
- [2]. Matthias Paul, et al. The Potency of New Muscle Relaxants on Recombinant Muscle-Type Acetylcholine Receptors. Anesth Analg. 2002 Mar;94(3):597-603; table of contents. [Content Brief]
- [3]. J E Caldwell. New Skeletal Muscle Relaxants. Int Anesthesiol Clin. Winter 1995;33(1):39-60. [Content Brief]
